Research programme: bacteria based therapeutics - Seres Therapeutics

Drug Profile

Research programme: bacteria based therapeutics - Seres Therapeutics

Alternative Names: SER 155; SER 301; SER-401

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seres Health
  • Developer Parker Institute for Cancer Immunotherapy; Seres Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Bacteria
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Metabolic disorders
  • Research Graft-versus-host disease; Inflammation; Ulcerative colitis

Most Recent Events

  • 14 Nov 2017 Seres, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy collaborate for SER 401 in Malignant melanoma
  • 14 Nov 2017 Preclinical trials in Cancer in USA (PO)
  • 14 Nov 2017 Seres Therapeutics plans a clinical trial for Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top